EPISODE · Jul 16, 2026 · 6 MIN
Aromatase Inhibitor Better than Tamoxifen for Initial Adjuvant Therapy for HR- Positive Breast Cancer, But Compliance an Issue!
from Oncology Times - OncTimes Talk
Cornelis van de Velde at ECCO15-ESMO34 on the largest comparison of an aromatase inhibitor with tamoxifen as initial adjuvant therapy for patients with hormone receptor-positive breast cancer--analysis of results from the TEAM (Tamoxifen Exemestane Adjuvant Multinational) study reported at ECCO15-ESMO34.
Embed this episode
NOW PLAYING
Aromatase Inhibitor Better than Tamoxifen for Initial Adjuvant Therapy for HR- Positive Breast Cancer, But Compliance an Issue!
0:00
6:57
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Oncology Times - OncTimes Talk?
This episode is 6 minutes long.
When was this Oncology Times - OncTimes Talk episode published?
This episode was published on July 16, 2026.
Can I download this Oncology Times - OncTimes Talk episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!